Pamidronate Disodium and Possible Ocular Adverse Drug Reactions

Macarol, Veronika; Fraunfelder, F. T.

doi:10.1016/s0002-9394(14)72902-2

Cited by 143 publications

(55 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, in¯ammatory side eects have also been reported in the ®eld of ophthalmology (Siris, 1993;Macarol & Frauenfelder, 1994). Our ®ndings suggest that the combined administration of an aminoBP (a potent inhibitor of bone resorption) with Cl 2 MBP (a less potent inhibitor of bone resorption) may be a useful regimen in that it might produce much weaker in¯ammatory side eects than use of an aminoBP alone, while possibly producing a stronger inhibitory eect on bone resorption than that obtained by the separate use of either agent.…”

Section: Proposal Of a Combined Clinical Use Of An Aminobp And Non-ammentioning

confidence: 92%

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non‐aminobisphosphonate

Endo

Shibazaki

Yamaguchi

et al. 1999

British J Pharmacology

View full text Add to dashboard Cite

1 When injected intraperitoneally into mice in doses larger than those used clinically, all the amino derivatives of bisphosphonates (aminoBPs) tested induce a variety of in¯ammatory reactions such as induction of histidine decarboxylase (HDC, the histamine-forming enzyme), hypertrophy of the spleen, atrophy of the thymus, hypoglycaemia, ascites and accumulation of exudate in the thorax, and an increase in the number of macrophages and/or granulocytes in the peritoneal cavity of blood. On the other hand, dichloromethylene bisphosphonate (Cl 2 MBP) a typical non-aminoBP, has no such in¯ammatory actions. In the present study, we found that this agent can suppress the in¯ammatory actions of aminoBPs. 2 Cl 2 MBP, when injected into mice before or after injection of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP; a typical aminoBP), inhibited the induction of HDC activity by AHBuBP in a dose-and time-dependent manner. The increase in HDC activity induced by AHBuBP was largely suppressed by the injection of an equimolar dose of Cl 2 MBP. Cl 2 MBP also inhibited other AHBuBP-induced in¯ammatory reactions, as well as the in¯ammatory actions of two other aminoBPs. However, Cl 2 MBP did not inhibit the increase in HDC activity induced by lipopolysaccharide (LPS). 3 We have previously reported that AHBuBP augments the elevation of HDC activity and the production of interleukin-1b (IL-1b) that are induced by LPS. These actions of AHBuBP were also inhibited by Cl 2 MBP. 4 Based on these results and reported actions of bisphosphonates, the mechanisms underlying the contrasting eects of aminoBPs and Cl 2 MBP, a non-aminoBP are discussed. The results suggest that combined administration of Cl 2 MBP and an aminoBP in patients might be a useful way of suppressing the in¯ammatory side eects of aminoBPs.

show abstract

Section: Proposal Of a Combined Clinical Use Of An Aminobp And Non-ammentioning

confidence: 92%

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non‐aminobisphosphonate

Endo

Shibazaki

Yamaguchi

et al. 1999

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…However, most NBPs have inflammatory side effects (such as fever, increase in acute-phase proteins, gastrointestinal disturbance, ophthalmic inflammation, and a serious influenza-like reaction in children with osteogenesis imperfecta) [2][3][4][5][6][7][8]. Unexpectedly, clinical applications have recently disclosed an additional serious side effect, jaw-bone necrosis and exposure, with about 400 patients having been reported to exhibit this effect in the space of a few years [9,10].…”

Section: Introductionmentioning

confidence: 99%

Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells

Xue

Funayama

et al. 2007

International Immunopharmacology

View full text Add to dashboard Cite

“…These symptoms could improve after discontinuation of the drug treatment. Intravenous nitrogen-containing BPs can 13 give undesirable inflammatory reactions (including an increase in acute-phase proteins, fever, flu-like symptoms, and ophthalmic inflammation) after the first infusion [1,43,69,73], which is thought to occur because of their potential to activate human γ,δ-T cells [74]. Notably, these symptoms do not recur with subsequent infusions.…”

Section: Potential Adverse Effectsmentioning

confidence: 99%

Use of bisphosphonates for the treatment of stress fractures in athletes

Shima

Engebretsen

Iwasa

et al. 2008

Knee Surg Sports Traumatol Arthrosc

View full text Add to dashboard Cite

A literature review was performed to investigate the potential role of bisphosphonates (BPs) for the treatment of stress fractures in athletes. Given the inhibitory action on osteoclast-mediated bone resorption, short-term suppression of bone remodeling using BPs could potentially treat stress fractures and prevent stress fractures to become regular fractures. To date, while there are some animal studies showing the scientific basis of BPs on stress fractures, we must say that there is still no conclusive evidence to prove any effect of BPs on stress fracture healing in humans. Further well-designed clinical trials should be carried out to establish their usefulness and safety. Until the results are available, it is prudent to limit the use of BPs for the treatment of stress fractures.

show abstract

Pamidronate Disodium and Possible Ocular Adverse Drug Reactions

Cited by 143 publications

References 6 publications

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non‐aminobisphosphonate

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non‐aminobisphosphonate

Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells

Use of bisphosphonates for the treatment of stress fractures in athletes

Contact Info

Product

Resources

About